334 related articles for article (PubMed ID: 33888356)
1. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
[TBL] [Abstract][Full Text] [Related]
2. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
[TBL] [Abstract][Full Text] [Related]
3. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Taplin ME; Montgomery B; Logothetis CJ; Bubley GJ; Richie JP; Dalkin BL; Sanda MG; Davis JW; Loda M; True LD; Troncoso P; Ye H; Lis RT; Marck BT; Matsumoto AM; Balk SP; Mostaghel EA; Penning TM; Nelson PS; Xie W; Jiang Z; Haqq CM; Tamae D; Tran N; Peng W; Kheoh T; Molina A; Kantoff PW
J Clin Oncol; 2014 Nov; 32(33):3705-15. PubMed ID: 25311217
[TBL] [Abstract][Full Text] [Related]
4. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.
McClintock TR; von Landenberg N; Cole AP; Lipsitz SR; Gild P; Sun M; Fletcher SA; Roghmann F; Menon M; Nguyen PL; Noldus J; Choueiri TK; Kibel AS; Trinh QD
Ann Surg Oncol; 2019 Jan; 26(1):297-305. PubMed ID: 30430324
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.
McKay RR; Berchuck J; Kwak L; Xie W; Silver R; Bubley GJ; Chang PK; Wagner A; Zhang Z; Kibel AS; Taplin ME
J Urol; 2021 Jun; 205(6):1689-1697. PubMed ID: 33502237
[TBL] [Abstract][Full Text] [Related]
8. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
9. Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study.
Casadei C; Scarpi E; Conteduca V; Gurioli G; Cursano MC; Brighi N; Lolli C; Schepisi G; Basso U; Fornarini G; Bleve S; Farolfi A; Altavilla A; Burgio SL; Giunta EF; Gianni C; Filograna A; Ulivi P; Olmos D; Castro E; De Giorgi U
Eur Urol Open Sci; 2024 Mar; 61():44-51. PubMed ID: 38384439
[TBL] [Abstract][Full Text] [Related]
10. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
11. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
[TBL] [Abstract][Full Text] [Related]
12. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
13. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.
Meyer F; Bairati I; Bédard C; Lacombe L; Têtu B; Fradet Y
Urology; 2001 Aug; 58(2 Suppl 1):71-7. PubMed ID: 11502453
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and Thromboembolic Events in Patients With Localized Prostate Cancer Receiving Intensified Neoadjuvant Androgen Deprivation: A Systematic Review and Meta-Analysis.
Felício de Campos E; Xavier CB; Queiroz MM; Firmino Lima Júnior N; Ilario EN; Coelho RF; Nahas WC; Bastos DA; Fontes Jardim DL
Clin Genitourin Cancer; 2024 Jun; 22(3):102088. PubMed ID: 38718699
[TBL] [Abstract][Full Text] [Related]
15. Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.
Wu Y; Yu H; Li S; Wiley K; Zheng SL; LaDuca H; Gielzak M; Na R; Sarver BAJ; Helfand BT; Walsh PC; Lotan TL; Cooney KA; Black MH; Xu J; Isaacs WB
Eur Urol Oncol; 2020 Apr; 3(2):224-230. PubMed ID: 31948886
[TBL] [Abstract][Full Text] [Related]
16. Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer.
Thomas HR; Chen MH; D'Amico AV; Bennett CL; Kattan MW; Sartor O; Stein K; Nguyen PL
Clin Genitourin Cancer; 2018 Aug; 16(4):313-317. PubMed ID: 29866496
[TBL] [Abstract][Full Text] [Related]
17. Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment.
Miocinovic R; Berglund RK; Stephenson AJ; Jones JS; Fergany A; Kaouk J; Klein EA
Urology; 2011 Apr; 77(4):946-50. PubMed ID: 21477723
[TBL] [Abstract][Full Text] [Related]
18. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
[TBL] [Abstract][Full Text] [Related]
19. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
20. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.
Wilkinson S; Ye H; Karzai F; Harmon SA; Terrigino NT; VanderWeele DJ; Bright JR; Atway R; Trostel SY; Carrabba NV; Whitlock NC; Walker SM; Lis RT; Abdul Sater H; Capaldo BJ; Madan RA; Gulley JL; Chun G; Merino MJ; Pinto PA; Salles DC; Kaur HB; Lotan TL; Venzon DJ; Choyke PL; Turkbey B; Dahut WL; Sowalsky AG
Eur Urol; 2021 Dec; 80(6):746-757. PubMed ID: 33785256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]